226 related articles for article (PubMed ID: 36950252)
1. Implications of the paradigm shift in management of
Graham DY
Therap Adv Gastroenterol; 2023; 16():17562848231160858. PubMed ID: 36950252
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibility testing before first-line treatment for
Cosme A; Montes M; Ibarra B; Tamayo E; Alonso H; Mendarte U; Lizasoan J; Herreros-Villanueva M; Bujanda L
World J Gastroenterol; 2017 May; 23(18):3367-3373. PubMed ID: 28566898
[TBL] [Abstract][Full Text] [Related]
3. Helicobacter pylori eradication rates in children upon susceptibility testing based on noninvasive stool polymerase chain reaction versus gastric tissue culture.
Vécsei A; Innerhofer A; Graf U; Binder C; Giczi H; Hammer K; Bruckdorfer A; Hirschl AM; Makristathis A
J Pediatr Gastroenterol Nutr; 2011 Jul; 53(1):65-70. PubMed ID: 21694538
[TBL] [Abstract][Full Text] [Related]
4.
Shiotani A; Roy P; Lu H; Graham DY
Therap Adv Gastroenterol; 2021; 14():17562848211064080. PubMed ID: 34987609
[TBL] [Abstract][Full Text] [Related]
5. Best Practices for
Graham DY
Gastroenterol Hepatol (N Y); 2024 Mar; 20(3):159-168. PubMed ID: 38680170
[TBL] [Abstract][Full Text] [Related]
6. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics.
Fallone CA; Moss SF; Malfertheiner P
Gastroenterology; 2019 Jul; 157(1):44-53. PubMed ID: 30998990
[TBL] [Abstract][Full Text] [Related]
7. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole.
Marzio L; Coraggio D; Capodicasa S; Grossi L; Cappello G
Helicobacter; 2006 Aug; 11(4):237-42. PubMed ID: 16882326
[TBL] [Abstract][Full Text] [Related]
8. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
[TBL] [Abstract][Full Text] [Related]
9. Novel and Effective Therapeutic Regimens for
Hu Y; Zhu Y; Lu NH
Front Cell Infect Microbiol; 2017; 7():168. PubMed ID: 28529929
[No Abstract] [Full Text] [Related]
10. Noninvasive molecular analysis of
Ierardi E; Giorgio F; Iannone A; Losurdo G; Principi M; Barone M; Pisani A; Di Leo A
World J Gastroenterol; 2017 Apr; 23(14):2453-2458. PubMed ID: 28465629
[TBL] [Abstract][Full Text] [Related]
11. Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection?
John A; Al Kaabi S; Doiphode S; Chandra P; Sharma M; Babu R; Yacoub R; Derbala M
Indian J Gastroenterol; 2015 Sep; 34(5):404-7. PubMed ID: 26541342
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility-guided therapy for Helicobacter pylori-infected penicillin-allergic patients: A prospective clinical trial of first-line and rescue therapies.
Luo L; Huang Y; Liang X; Ji Y; Yu L; Lu H
Helicobacter; 2020 Aug; 25(4):e12699. PubMed ID: 32428369
[TBL] [Abstract][Full Text] [Related]
13. Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori.
Bardhan KD; Morton D; Perry MJ; Sanders DS; Morris P; Rowland A; Thompson M; Mitchell TR; Roberts PM
Aliment Pharmacol Ther; 2001 Aug; 15(8):1199-204. PubMed ID: 11472323
[TBL] [Abstract][Full Text] [Related]
14. Eradication rate of Helicobacter Pylori infection is directly influenced by adherence to therapy in children.
Kotilea K; Mekhael J; Salame A; Mahler T; Miendje-Deyi VY; Cadranel S; Bontems P
Helicobacter; 2017 Aug; 22(4):. PubMed ID: 28303625
[TBL] [Abstract][Full Text] [Related]
15. [Detection of Helicobacter pylori and antimicrobial resistance in gastric biopsy specimens].
Cağdaş U; Otağ F; Tezcan S; Sezgin O; Aslan G; Emekdaş G
Mikrobiyol Bul; 2012 Jul; 46(3):398-409. PubMed ID: 22951652
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic susceptibility of Helicobacter pylori in Iceland.
Gunnarsdottir AI; Gudjonsson H; Hardardottir H; Jonsdottir KD; Bjornsson ES
Infect Dis (Lond); 2017 Sep; 49(9):647-654. PubMed ID: 28440099
[TBL] [Abstract][Full Text] [Related]
17. Helicobacter pylori antimicrobial resistance in a pediatric population.
Silva GM; Silva HM; Nascimento J; Gonçalves JP; Pereira F; Lima R
Helicobacter; 2018 Oct; 23(5):e12528. PubMed ID: 30091503
[TBL] [Abstract][Full Text] [Related]
18. 'Rescue' therapies for the management of Helicobacter pylori infection.
Di Mario F; Cavallaro LG; Scarpignato C
Dig Dis; 2006; 24(1-2):113-30. PubMed ID: 16699270
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
[TBL] [Abstract][Full Text] [Related]
20. Helicobacter pylori treatment and antibiotic susceptibility: results of a five-year audit.
Fraser AG; Moore L; Hackett M; Hollis B
Aust N Z J Med; 1999 Aug; 29(4):512-6. PubMed ID: 10868529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
